AN2 Therapeutics
antibacterial activity in a chronic model of mac lung disease in showed improved antibacterial activity of at all doses compared to the daily humanized dose of lung disease in mice against an therapeutics | AN2 Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
March 2022
Slide
16 of 27
Similar slides by AN2 Therapeutics
See diffirences between slides (animation)
Investor Presentation
August 2022
antibacterial activity in a chronic model of mac lung disease in mice significant reductions in mac with superior decreases with soc regimen compared to soc alone an therapeutics | AN2 Therapeutics
Investor Presentation
August 2022
antibacterial activity in a chronic model of mac lung disease in mice showed improved antibacterial activity of at all doses compared to the daily humanized dose of an therapeutics | AN2 Therapeutics
IPO
March 2022
antibacterial activity in a chronic model of mac lung disease in mice significant reductions in mac with superior decreases with soc regimen compared to soc alone an therapeutics | AN2 Therapeutics
Related slides by other companies
23andMe
Investor Presentation
January 2024
in respiratory disease beyond | 23andMe
Other recent decks by AN2 Therapeutics
See all presentations (2 decks)
Investor Presentation
August 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io